X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:

Pacific Biosciences Releases Software to Detect DNA Base Modifications Using the PacBio® RS

Monday, June 18, 2012

Researchers Now Have the First Ever Tool to Detect Epigenetic and

Other DNA Modifications Simultaneously within the Sequencing Workflow

MENLO PARK, Calif.–(BUSINESS WIRE)–

Pacific Biosciences of California, Inc., (NASDAQ:PACB) today launched a

new and unique solution to detect DNA base modifications associated with

epigenetic regulation and DNA damage using the PacBio® RS High

Resolution Genetic Analyzer.

DNA base modifications such as methylation have an important role in a

wide variety of biological processes such as growth and aging, immunity,

bacterial pathogenicity, and disease development. The new analysis

software for the PacBio® RS enables customers to

detect and visualize these DNA modifications. The software works by

measuring the rate of DNA base incorporation during sequencing. This

information, automatically gathered during the sequence process, is a

unique feature of the company’s single molecule, real-time (SMRT®)

technology.

“We are pleased to provide the first and only tool that offers

researchers worldwide the ability to detect base modifications as an

integral part of the sequencing workflow,” said Kevin Corcoran, Senior

Vice President of Market Development at Pacific Biosciences. “This is a

major milestone for Pacific Biosciences and a valuable new tool for the

scientific community.”

The SMRT Analysis software upgrade is available to scientists through a

free download from PacBio’s DevNet portal. The analysis tool works on

any data generated by the PacBio RS with its latest C2 chemistry,

enabling researchers to re-analyze existing data to detect methylation

and other base modifications.

More than 20 biologically important DNA base modifications are known,

and new types continue to be discovered. The initial software release

simplifies the process of detecting these modification events in native

genomic DNA through a user-friendly analysis and visualization

interface. Guidelines on studying the methylomes of bacteria, including

N6-methyladenine and N4-methylcytosine, are also available on the

company’s website at www.pacb.com/basemod.

“Modifications such as methylation have been shown to be critical in

influencing disease onset and severity, the pathogenicity of bacteria,

and gene regulation,” said Eric Schadt, Ph.D., Director of the Institute

for Genomics and Multiscale Biology at Mt. Sinai Hospital and Chief

Science Officer at Pacific Biosciences. “The work we have done using

SMRT sequencing to resolve the German E. coli outbreak strain,

for example, points to a crucial role for base modification in the

regulation of a gene associated with the strain’s severity. If we aren’t

looking at base modifications, we aren’t seeing the whole picture in the

biology of pathogens.”

Dr. Schadt is speaking today about his work using the SMRT technology

during the President’s Forum at the annual American Society for

Microbiology’s 112th General Meeting in San Francisco. The

talk is entitled, “Whole-genome Characterization of Methyladenine

Residues in Highly Pathogenic Strains of E. coli and V.

cholerae and Their Impact on Function.”

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ: PACB) offers the PacBio®

RS, a high resolution genetic analyzer, to help scientists solve

genetically complex problems. Based on its novel single molecule,

real-time (SMRT®) technology, the company’s products enable:

targeted sequencing to more comprehensively characterize genetic

variations; de novo genome assembly to more fully identify,

annotate and decipher genomic structures; and DNA base modification

identification to help characterize epigenetic regulation and DNA

damage. By providing access to genetic information that was previously

inaccessible, Pacific Biosciences enables scientists to increase their

understanding of biological systems.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking

statements may contain words such as “believe,” “may,” “estimate,”

“anticipate,” “continue,” “intend,” “expect,” “plan,” the negative of

these terms, or other similar expressions, and include the assumptions

that underlie such statements. Such statements include, but are not

limited to, statements regarding the Company’s SMRT technology. These

statements are subject to known and unknown risks and uncertainties that

could cause actual results to differ materially from those expressed or

implied by such statements, including but not limited to risks discussed

from time to time in documents Pacific Biosciences of California, Inc.

has filed with the Securities and Exchange Commission, including the

risks identified under the section captioned “Risk Factors” in its

recently filed Quarterly Report on Form 10-Q. All forward-looking

statements are based on estimates, projections and assumptions as of the

date hereof. Pacific Biosciences undertakes no obligation to update any

forward-looking statements.

Media:
For Pacific BiosciencesNicole

Litchfield, 415-793-6468
nicole@bioscribe.com
or
Investors:
Pacific

BiosciencesTrevin Rard, 650-521-8450
ir@pacificbiosciences.com

Source: Pacific Biosciences of California, Inc.

News Provided by Acquire Media